We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Economic Return of Clinical Trials Performed Under the Pediatric Exclusivity Program.
- Authors
Li, Jennifer S.; Eisenstein, Eric L.; Grabowski, Henry G.; Reid, Elizabeth D.; Mangum, Barry; Schulman, Kevin A.; Goldsmith, John V.; Murphy, Dianne; Califf, Robert M.; Benjamin, Jr, Daniel K.
- Abstract
The article offers a look at a medical study done to research the economic return to the drug industry of clinical trials done under the pediatric exclusivity program in the United States. According to the article, the U.S. Food and Drug Administration was granted extensions of marketing rights through the Pediatric Exclusivity Program, which has been criticized for being an unexpected gain to the innovator drug industry. The results of the study show a broad representation of the program, including asthma, tumors, hypertension, and depression. The economic return was found to be variable.
- Subjects
MEDICAL research; PHARMACEUTICAL industry &; economics; UNITED States. Food &; Drug Administration; CLINICAL trials; PEDIATRICS; DRUG marketing; ASTHMA; TUMORS; HYPERTENSION
- Publication
JAMA: Journal of the American Medical Association, 2007, Vol 297, Issue 5, p480
- ISSN
0098-7484
- Publication type
Article
- DOI
10.1001/jama.297.5.480